← All countries · Europe
98%
MCV1
2025 · WHO/UNICEF estimate
99%
DTP3
2025 · WHO/UNICEF estimate
99%
IPV complete
2025 · WHO/UNICEF estimate
99%
HepB3
2025 · WHO/UNICEF estimate
21
Measles cases
2025 reported
20
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 98%2015 · WHO/UNICEF estimate | — | D · poor | |
| DTP1First dose of diphtheria-tetanus-pertussis | 99%2025 · WHO/UNICEF estimate | — | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 99%2025 · WHO/UNICEF estimate | 98.5% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 99%2025 · WHO/UNICEF estimate | — | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | 99%2025 · WHO/UNICEF estimate | 98.5% | C · weak | |
| MCV1First dose of measles-containing vaccine | 98%2025 · WHO/UNICEF estimate | 98.4% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 95%2025 · WHO/UNICEF estimate | 95.4% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 98%2025 · WHO/UNICEF estimate | 98.4% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 99%2025 · WHO/UNICEF estimate | 98.5% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 98%2025 · WHO/UNICEF estimate | — | B · good | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 99%2025 · WHO/UNICEF estimate | 98.5% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | —% · Administrative (country-reported) | — | too few points | D · poor |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 98%2025 · WHO/UNICEF estimate | 97.6% | A · strong | |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | no data |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 97%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 95%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 96%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 212025 | 2per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 882025 | 8.5per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 202025 | 1.9per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | C · weak | |
| Polio (paralytic) all countries · vaccine evidence | 02022 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 02020 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 532025 | 5.1per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 1252025 | 12per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (66 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | D0-Y5 | Risk group(s) | Specific risk group |
| CHIKUNGUNYAChikungunya vaccine | 1 | Travellers | Travellers | |
| CHOLERACholera vaccine | 1 | Travellers | Travellers | |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with with chronic conditions, other groups | |
| DENGUEDengue vaccine | 1 | Travellers | Travellers | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M2 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M6 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 2 | M4 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 4 | M18 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 5 | Y5 | General/routine | |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Health workers | Specific risk groups (pre and post-exposure), including non-immune Healthcare professionals with direct and ongoing contact with people with acute hepatitis A; professionals involved in the collection and processing of biological samples from suspected or confirmed hepatitis A cases. | |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Risk group(s) | Specific risk groups (pre and post-exposure), including non-immune Healthcare professionals with direct and ongoing contact with people with acute hepatitis A; professionals involved in the collection and processing of biological samples from suspected or confirmed hepatitis A cases. | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | Risk group(s) | Specific risk groups (pre and post-exposure) | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Health workers | Specific risk groups, including healthcare workers | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Risk group(s) | Specific risk groups, including healthcare workers | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | |
| HIBHib (Haemophilus influenzae type B) vaccine | 1 | Risk group(s) | Specific risk groups | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y10 | HPV administered to females and males | Females and males |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M6 | HPV administered to females and males | Females and males |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >=Y60 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | Risk group(s) | All adults who were not vaccinated during childhood | |
| JE_INACTDJE-Inact (Japanese Encephalitis inactivated) vaccine | 1 | Travellers | Travellers | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | M12 | General/routine | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Risk group(s) | Specific risk groups | |
| MEN_BMeningococcal B vaccine | 1 | M2 | General/routine | |
| MEN_BMeningococcal B vaccine | 1 | Risk group(s) | Specific risk groups | |
| MEN_BMeningococcal B vaccine | 2 | M4 | General/routine | |
| MEN_BMeningococcal B vaccine | 3 | M12 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Risk group(s) | Specific risk group | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y5 | General/routine | |
| MPOXMpox (monkeypox) vaccine | 1 | 1st contact | Health workers | Specific risk groups (pre and post-exposure), namely asymptomatic individuals aged 18 years or older who have never been diagnosed with mpox and who are at increased risk of exposure; and healthcare professionals with direct and ongoing contact with people with mpox, or professionals involved in the collection and processing of biological samples from mpox cases. |
| MPOXMpox (monkeypox) vaccine | 1 | 1st contact | Risk group(s) | Specific risk groups (pre and post-exposure), namely asymptomatic individuals aged 18 years or older who have never been diagnosed with mpox and who are at increased risk of exposure; and healthcare professionals with direct and ongoing contact with people with mpox, or professionals involved in the collection and processing of biological samples from mpox cases. |
| MPOXMpox (monkeypox) vaccine | 2 | D28 | Health workers | Specific risk groups (pre and post-exposure), namely asymptomatic individuals aged 18 years or older who have never been diagnosed with mpox and who are at increased risk of exposure; and healthcare professionals with direct and ongoing contact with people with mpox, or professionals involved in the collection and processing of biological samples from mpox cases. |
| MPOXMpox (monkeypox) vaccine | 2 | D28 | Risk group(s) | Specific risk groups (pre and post-exposure), namely asymptomatic individuals aged 18 years or older who have never been diagnosed with mpox and who are at increased risk of exposure; and healthcare professionals with direct and ongoing contact with people with mpox, or professionals involved in the collection and processing of biological samples from mpox cases. |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | M2 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | Risk group(s) | Specific risk groups | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 2 | M4 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 3 | M12 | General/routine | |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | Risk group(s) | Specific risk groups | |
| RABIESRabies vaccine | 1 | Risk group(s) | Specific risk groups (pre and post-exposure) | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | M2 | Risk group(s) | Specific risk groups |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | M4 | Risk group(s) | Specific risk groups |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | M2 | Risk group(s) | Specific risk groups |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | M4 | Risk group(s) | Specific risk groups |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | M6 | Risk group(s) | Specific risk groups |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | B | General/routine | All children born between August 1, 2024, and March 31, 2025. |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | Risk group(s) | All preterm children with a gestational age of up to 33 weeks + 6 days, born between January 1 and July 31, 2024. All children with other risk factors for severe RSV infection, entering their first or second RSV season, who have not yet reached 24 months of age by September 30, 2024. | |
| TBE_ADULTAdult TBE (tick borne encephalitis) vaccine | 1 | Travellers | Travellers | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Pregnant women | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Y25 | Adults | Adults |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | Y45 | Adults | Adults |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | Y65 | Adults | Adults |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y10 | Adults | Adults |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y10 | Adults | Adults |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | Y10 | General/routine | |
| TYPHOID_PSTyphoid polysaccharide vaccine | 1 | Travellers | Travellers | |
| YFYF (Yellow fever) vaccine | 1 | Travellers | Travellers | |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | Risk group(s) | Specific risk group |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.